(Boursier.com) – OSE Immuno jumped 6% to more than 10 euros this Monday morning, boosted by a recommendation from Degroof Petercam, the purchase on the record with a price target of 15.52 euros. The intermediary highlights the value proposition of OSE’s core asset, Tedopi, and BI 765063 for cancer patients, based on recent clinical results. With additional active ingredients in development for autoimmune diseases, OSE has several strengths. Thus, the research firm sees a potential upwards of more than 60% on Friday’s prices and recommends the purchase. The main potential catalyst in the short term is the return of regulators regarding the Phase 3 study with Tedopi in ‘non-small cell’ lung cancer.
In the sum of the parts evaluated by the broker, Tedopi in non-small cell lung cancer represents a share of 38%.
© 2022 Boursier.com